- Home
- SDST vs CUE Comparison
SDST vs CUE Comparison
Compare SDST & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | CUE |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 27.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SDST | CUE |
|---|---|---|
| Price | $2.41 | $0.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $3.00 |
| AVG Volume (30 Days) | 60.5K | ★ 717.6K |
| Earning Date | 03-17-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.14 | $0.23 |
| 52 Week High | $7.67 | $1.05 |
Technical Indicators
Market Signals| Indicator | SDST | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 28.90 | 37.44 |
| Support Level | $0.29 | $0.23 |
| Resistance Level | $3.00 | $0.35 |
| Average True Range (ATR) | 0.26 | 0.03 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 11.93 | 15.15 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.